Skip to Main Content

Heidi Mansour

Professor & Program Leader

Center for Translational Science, Environmental Health Sciences

Office: CTS 314

Phone: 772-345-4731



  • University of North Carolina at Chapel Hill, School of Pharmacy, Postdoctoral Fellow, 06/2008
  • University of Wisconsin-Madison, Ph.D. Pharmaceutical Sciences, 12/2003
  • University of Wisconsin-Madison, School of Pharmacy, B.S. Pharmacy (Distinction & Honors), 05/1996

Health Professional License

Registered Pharmacist (R.Ph.), 08/1996-Present


In 2022, Dr. Heidi Mansour was elected to the American Institute of Medical and Biological Engineers College of Fellows.

Watch the ceremony:


Encinas-Basurto, D., Konhilas, J., Polt, R., Hay, M., and Mansour, H.M. Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release U Pharmaceutics: Special Issue on Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside (2022) 14 (3): 587.

Ruiz, V.H., Encinas-Basurto, D., Sun, B., Eedara, B.B., Dickinson, S., Wondrak, G., Chow, S., Curiel, C., and Mansour, H.M. Design, Physicochemical Characterization, In Vitro Human Cell Culture,and In Vitro Permeation of Innovative Topical Formulations of Resatorvid for Targeted Skin Drug Delivery Pharmaceutics: Special Issue on Skin Drug Delivery for Local and Systemic Applications  (2022) 14 (4): 700.

Hoyer-Kimura, C.H., Konhilas, J., Mansour, H.M., Polt, R., Doyle, K., Billheimer, D., and Hay, M. Neurofilament Light: A Possible Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia. Journal of Neuroinflammation (2021) 18(1):236.

Alabsi, W., Acosta, M.F., Al-Obeidi, F.A., Hay, M., Polt, R., and Mansour, H.M.  Synthesis, Physicochemical Characterization, In Vitro Human Cellular Studies, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 Glycopeptide with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers. UPharmaceutics: Special Theme Issue on Women in PharmaceuticsU (2021) 13(8): 1278.

Alabsi, W., Al-Obeidi, F.A., Polt, R., and Mansour, H.M.  Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical  Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. UPharmaceutics: Special Theme Issue: Non-Invasive Drug Delivery SystemsU (2021) 13 (1): 26.

Muralidharan, P, Hayes, D. Jr., Fineman, J.R., Black, S.M., and Mansour, H.M.  Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (ROCK) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery. 20TUPharmaceutics: Special Issue on Medical Aerosol Drug Delivery (2021) 13 (12): 2188.

Eedara, B.B., Alabsi, W., Encinas-Basurto, D., Polt, R., Ledford, J.G., and Mansour, H.M. Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. UPharmaceutics: Special Theme Issue on Methodology, Design and Regulatory Considerations for the Bioequivalence of Oral Inhaled ProductsU (2021)13(7):1077.

Mitchell, J.P., Berlinski, A., Canisius, S., Cipolla, D., Dolovich, M.B., Gonda, I., Hochhaus, G., Kadrichu, N., Lyapustina, S., Mansour, H.M., Darquenne, C., Clark, A.R., Newhouse, M., Ehrmann, S., Humphries, R., and Boushey, H. An Urgent Appeal to Clinical Decision-Makers and Governmental Agencies Involved with Public Health to Consider the Potential for Medication Delivery in the Context of COVID-19 Therapies Using the Inhaled Route of Administration: A Statement from the International Society for Aerosols in Medicine (ISAM) Regulatory and Standardization Issues Networking Group. UJournal of Aerosol Medicine & Pulmonary Drug DeliveryU (2020) 33 (4): 235–238.

Muralidharan, P, Jones, B., Allaway, G., Biswal, S.S., and Mansour, H.M.  Design and Development of Innovative Microparticulate/Nanoparticulate Inhalable Dry Powders of a Novel Synthetic Trifluorinated Chalcone Derivative and Nrf2 Agonist. 20TUScientific Reports U (2020) 10(1):19771.

Acosta, M.F., Muralidharan, P, Grijalva, C.L., Abrahamson, M.D., Hayes, D. Jr., Fineman, J.R., Black, S.M., and Mansour, H.M. Advanced Therapeutic Inhalation Aerosols of a Nrf2 Activator and RhoA/Rho Kinase (ROCK) Inhibitor for Targeted Pulmonary Drug Delivery in Pulmonary Hypertension: Design, Characterization, Aerosolization, In Vitro 2D/3D Human Lung Cell Cultures, and In Vivo Efficacy. UTherapeutic Advances in Respiratory DiseaseU (2021) 15:1-25.

Muralidharan, P., Acosta, M.F., Gomez, A.I., Grijalva, C., Tang, H., Yuan, J. X.-L. and Mansour, H.M.  Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy. UAntioxidants: Special Theme Issue: Antioxidants and Lung DiseasesU 20T(2021) 10 (3) 427.

Acosta, M.F., Abrahamson, M.D., Encinas-Basurto, D., Fineman, J.R., Black, S.M., and Mansour, H.M.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers. UThe AAPS Journal: Special Theme Issue: Celebrating Women in the Pharmaceutical Sciences U(2021) 23 (1): 1-14.

Acosta, M.F., Muralidharan, P., Abrahamson, M.D., Grijalva, C.L, Carver, M., Tang, H., Klinger, C., Fineman, J.R., Black, S.M., and Mansour, H.M.  Comparison of L-Carnitine and L-Carnitine HCL Salt for Targeted Lung Treatment of Pulmonary Hypertension (PH) as Inhalation Aerosols: Design, Comprehensive Characterization, In Vitro 2D/3D Human Lung Cell Cultures, and In Vivo MCT-Rat Model of PH. UPulmonary Pharmacology & TherapeuticsU (2020) 65:101998.

Gomez, A.I., Acosta, M.F., Muralidharan, P, Yuan, J. X.-L., Black, S.M., Hayes, D. Jr.,and Mansour, H.M. Advanced Spray-Dried Proliposomes of Amphotericin B as Microparticles/Nanoparticles as Dry Powder Inhalers for Targeted Pulmonary Drug Delivery. 20TUPulmonary Pharmacology & TherapeuticsU (2020) 64:101975.

Muralidharan, P, Mallory, E.K., Malapit, M., Phan, H., Ledford, J.G., Hayes, D. Jr, and Mansour, H.M.Advanced Nanoparticle/Microparticle Dual-Drug Combination Lactose Carrier-Free Dry Powder Inhalation Aerosols. 20TURSC AdvancesU (2020) 10: 41846-41856.

Muralidharan, P, Hayes, D. Jr., Black, S.M., and Mansour, H.M.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway. UThe Royal Society of Chemistry Molecular Systems Design & EngineeringU (2016) 1: 48-65. (Front Cover Page & Article).

Muralidharan, P., Malapit, M., Mallory, E., Hayes, D. Jr., and Mansour, H.M. Inhalable Nanoparticulate Powders for Respiratory Delivery. UNanomedicine: Nanotechnology, Biology, and MedicineU (2015) 11: 1189-1199.

Muralidharan, P., Hayes, D. Jr., and Mansour, H.M.  Dry Powder Inhalers in COPD, Lung Inflammation, and Pulmonary Infections. UExpert Opinion on Drug DeliveryU (2015) 12 (6): 947-962.

Vega, M.R., Dodson, M., Gross, C., Mansour, H.M., Lantz, R. C., Chapman, E., Wang, T., Black, S.M., Garcia, J.G., and Zhang, D.  Role of Nrf2 and Autophagy in Acute Lung Injury. UCurrent Pharmacology Reports:  Free Radicals MedicineU (2016) 2 (2): 91-101.

Lu, Q., Harris, V.A., Kumar, S., Mansour, H.M., and Black, S.M.Autophagy in Neonatal Hypoxia Ischemic Brain is Associated with Oxidative Stress. URedox BiologyU (2015) 6:516-523.

Google Scholar Link for full pubs listing with details and H-Index factor